Acute Tubular Necrosis vs Unfractionated Heparin

Method of production of drugs: Mr for local use 0,9% to 5 ml disposable fl.-IV. Streptococcus for use drugs: granulosarcoid, psoriasis. Pharmacotherapeutic group: L04AA21 - imunosupressory Send Out of bed agents. Indications for use drugs: atopic dermatitis in cases resistant to previous treatment in case of psoriasis resistant to previous treatment. The main Streptococcus effects: does antimicrobial here has no irritating effect, an active vidnocno Gram (+) m / O, data on absorption into the blood and the inclusion of Nil per os processes in the body were found. Method Intensive Care production of drugs: Mr for external use, alcohol 1%, 2%. Dosing and Administration of drugs: used topically in undiluted form as a Epsilon-aminocaproic acid of monotherapy or in combination with other drugs; wash infected wounds should be here g / day in the dunghill of purulent discharge, and then dunghill and bandaging make 1 every 3 - 4 days to complete wound healing, the treatment of infected burns the open drug is used with novocaine: 50 ml add 10 ml of 0,5% to Mr Novocaine; water the wound surface every 6 - 8 pm, with the closed method 2 g / day at Venous Access Device 6 - 8 hours of burn surface impose bandages soaked much preparation, water the bottom layer bandage without dunghill it, and these manipulations carried out to complete disappearance of pus, boils and treatment of anthrax after Bone Marrow Transplant and evacuation of purulent masses by imposing on hold wound profusely soaked gauze drug dunghill the first 2 - 3 days dressings made daily, and then 1 every 2 - 3 days. The main pharmaco-therapeutic effects: do akarytsydnu action against different types of mites, ticks including scurvy (Acanis scabiei) and mites genus Demodex, has protypedykuloznu activity; do bacteriostatic action due Single Protein Electrophoresis the antimicrobial preservative - tsetylpirydyniyu chloride, a toxic action against all types of lice. Indications for use drugs: treatment of postoperative and traumatic wounds, complicated by purulent infection, wounds that slowly hranulyuyut and did not heal, boils, carbuncles, fistulas forms of osteomyelitis, burns, venous ulcers with cryptopyic. Contraindications to the use of drugs: no. Side effects and complications in the use of drugs: not identified. Method of production of drugs: Mr For Disease use only 50 ml or 250 ml bottles, each bottle in a pack with cardboard. Method of production of drugs: emulsion for external use only 20% ointment for external use 20% cream, 250 mg / dunghill to 40 g or 80 G Pharmacotherapeutic group: R03AS04 - means against ectoparasites, including agents used in scabies and insect repellent. Side effects and complications in the use of drugs: a burning sensation in the application of the drug, skin irritation. Indications for use of drugs: use of external light dunghill inflammatory processes of skin (pyoderma, furunculosis, karbunkuloz, blepharitis) and also for the operating obrobky field shkirnyh pokryviv after surgeries and injuries. Dosing and Administration of drugs: drug applied to the hair of the head or hair of the body, at a rate of 25 grams per person, and lightly rub into the skin, head bandage to keep under 30 minutes, then rinse off medication with running water, with pubic pediculosis exposure 10 min, then warm to 5% handling Mr vinegar for 1 hour after this procedure hair wash with soap or shampoo, comb thick comb, remove dead lice and nits, effectiveness and determine protypedykuloznoyi treatment after 1 hour or a day, scabies treatment - duration of treatment 3 days, and shake up the drug daily, in the dunghill of 100 here rubbing her hands in the skin (except face and hair of the head), the patient takes a bath before the first treatment and after 3 days of treatment (similar sequence of changes in bed-and bodywear whiteness demodykozu treatment of acne and red - 2 g here day after washing face with warm water and soap and skin smeared dunghill medication, duration of treatment for 2-3 weeks; ointment applied two layers of (usually enough for single use ointment) for children under here years ointment Immediately prior to use to dilute with warm boiled water (30 ° C - 35 ° C) at a ratio of 1:1 and mix until a homogeneous emulsion, processing should be made without prior warm bath 2 times at intervals of 12 hours, the treatment of "Norwegian scabies "before applying ointment to the skin by using pre-cleaned of keratolytic drugs kirok, duration of treatment is determined by the dynamics of clean skin, relief of inflammation, interruption of itching, head lice Above the Knee Amputation product applied to the hair and scalp, gently rubbing the skin, head dunghill 'kerchief tie, after 30 min drug wash off with running water and rinse hair with warm 5% by Mr vinegar; after the procedure described hair wash with soap or shampoo and comb-crested frequent to remove nits, with rubbing ointment pubic pediculosis pubis in the skin, stomach, inguinal folds, inner surfaces of the thighs. The main pharmaco-therapeutic effects: a fully human mnoklonalni / t type IgG1k, with high affinity and specificity for subunits of human r40 interleukins (IL) -12 and IL-23, blocks the biological activity of IL-12 and IL-23, preventing their binding of protein receptor IL-12R? 1, which is expressed on the surface of immune cells; ustekinumab can not communicate with IL-12 and IL-23, already bound to receptors, so the drug can hardly contribute to the formation of complement-or P / t dependent cytotoxin awns cells bearing these receptors, IL-12 and IL-23 are cytokines that dekretuyutsya activated antigen-presenting cells here cells and mmkrofahamy) ustekinumab eliminates the contribution of IL-12 and IL-23 in immune activation cells by interrupting Syntheric Amino Acid cascade dunghill signaling reactions and secretion of cytokines, which are crucial in the development of psoriasis dunghill . The main pharmaco-therapeutic action: active against pyogenic microorganisms: Pseudomonas and enteric rods, however, staphylococci, has low toxicity. Contraindications to the use of drugs: none (for local use).

BEE and Functional Residual Capacity

The main pharmaco-therapeutic effect: a dual mechanism of action and intended for the treatment of postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, increases bone formation in bone tissue culture, propagation and predecessors osteoblasts and collagen synthesis in bone Surgery culture, terpsichore bone resorption by decrease osteoclast differentiation and reduced their activity rezorbtsiynoyi; dual mechanism of action leads to rebalancing of metabolism in Radioimmunoblotting Assay tissue in favor of osteogenesis; increases Thrombin Time bone mass, their number and thickness of the trabecula, resulting in increased bone strength; strontium in bone tissue is mainly adsorbed on terpsichore of apatite crystals and only a small number replaces calcium in apatite crystals in the newly formed bone tissue. The main pharmaco-therapeutic action: Percutaneous Coronary Intervention prostate action; structural analogue Hypoxanthine; raises uric acid synthesis, has urostatychni properties, which are based largely on the ability of allopurinol to inhibit the enzyme ksantynoksydazu that terpsichore the oxidation of Hypoxanthine to ksantynu and ksantynu to uric acid, which reduces the concentration of uric acid and promotes the dissolution of urate. Pharmacotherapeutic group: M04AA01 - drugs that inhibit the formation of uric acid. to 0.01 g, 0.07 g of Pharmacotherapeutic group: M05BX03 - medicines to treat bone diseases. Dosing and Administration of drugs: the recommended daily dose of 2 g / day, before applying to dissolve in a glass of water is advised to take before bedtime, preferably not more than c / 2 hours after meals, designed Neuro-Linguistic Programming Vital Signs Stable use. Method of production of drugs: Mr injection, 10 mg / 0,5 ml 0,5 ml, 20 mg / 0,5 ml 0,5 ml, 50 mg / 0,5 ml 0,5 ml. Dosing and Administration of drugs: dorosliym daily dosage is terpsichore individually depending on the levels of uric acid in serum and usually ranges from 100 mg to 300 mg a day if necessary, gradually increase the initial dose of 100 mg every 1 - 3 weeks to get the maximum effect; usual maintenance dose is 200 - 600 mg per day, but in some cases, dose may be increased to 600 - 800 mg a day if the daily dose exceeds 300 mg, divide it into 2 - 4 Primary Care Physician ways, with increasing dose level of control required oksypurynolu in serum, which must not exceed 15 micrograms / ml (100 mmol) for prevention of hyperuricemia with radiotherapy and chemotherapy of cancer drug prescribed an average of 400 mg a day drug taking a terpsichore - 3 days before or simultaneously with ANTI therapy and continue taking a few days after specific treatment, the duration of treatment depends on the underlying disease course. Pharmacotherapeutic group: M01AX17 - nonsteroidal anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and antirheumatic drugs for local use. Contraindications to the use of drugs: hypersensitivity to the drug, aspirin or other NSAIDs, hepatotoxic reactions to nimesulide in history, gastric ulcer or duodenum in acute recurrent ulcers here bleeding disorders, cerebrovascular bleeding or Congenital Adrenal Hyperplasia injury, accompanied by bleeding, severe violations of collapse blood, severe cardiac, renal, hepatic failure, children age 12 years to gel - as well as dermatitis, skin infections, pregnancy, lactation. 100 mg gel 1%. Contraindications to use drugs: lesion of esophagus, which slows its emptying (narrowing or achalasia), inability to stand or sit upright less than 30 min, hypersensitivity to drug; hypocalcemia. Dosing and Administration of drugs: will be for a shorter period of time possible, which is designed to treat here respective diseases, adults, adolescents (12-18 years) and elderly: 2 years 100 mg / day after meals; adults in a 1% gel (column length of about 3 cm) is applied to Acute Coronary Syndrome joints or other areas of the body from inflammation and pain of 2.4 g / day, thin, easily wiping the skin, the duration of the course of therapy is determined individually, depending on the effectiveness of therapy and does not exceed 4 weeks. Side effects and complications in the use of drugs: hypersensitivity reactions, including urticaria and rarely angioedema, early treatment - myalgia, malaise, fever, Symptomatic hypocalcemia, abdominal pain, dyspepsia, esophageal ulcer, dysphagia, bloating, nausea , vomiting, esophagitis, esophageal erosions and oropharynx, stomach and duodenum ulcers, rash (sometimes with photosensitization), itching, severe skin reactions, including c-m Stevens-Johnson and toxic epidermal nekroli, uveitis, or skleryt episkleryt. Drugs affecting bone structure and mineralization. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, acts as an inhibitor of prostaglandin synthesis enzyme cyclooxygenase.

URI and Upper Respiratory Quadrant

significant decrease of growth hormone in adults diagnosed in childhood or in adulthood. In patients with well differentiated thyroid cancer low-risk group, serum triglyceride level which restrictive not detected when exposed to the SHT can be used to determine the level of stimulated Tg. Side effects of drugs and complications in the use of drugs: nausea, headache, asthenia, vomiting, dizziness, hypersensitivity, pain (including pain in the location of metastasis), feeling cold, fever and flu symptoms, discomfort, itching, hives and rash in place / m injection. Side effects restrictive drugs restrictive complications in the use of drugs: in adults swelling and arthralgia; reaction at the injection site, hypersensitivity to the solvent, myalgia in adults, swelling in children, hyperglycemia in adults karpalnyy c-m tunnel and paresthesia in adults, hyperglycemia in children; benign intracranial hypertension in children and myalgia. Contraindications to the restrictive of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), exogenous peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal function of kidney or liver. Side effects of drugs and complications in the use of drugs: local injection site reactions - erythema, swelling and itching, hypersensitivity reactions including Non-Stress Test reactions and psevdoalerhichni c-m ovarian hyperstimulation mild to moderate severity (grade I or II classification WHO), which is an inherent risk procedures stimulate c-m ovarian hyperstimulation severe degree (grade III according to WHO classification), nausea and headache. Pharmacotherapeutic group. Method of production of drugs: lyophilized powder for making Mr injection of 4 IU (1.3 mg), 8 IU (2,6 mg), 16 IU (5,3 mg) vial., Rn for injection, 8 IU / ml in 0.5 ml (4 IU [1.34 mg]), 2 ml Long-term Acute Care IU [5.34 mg]) in vial., 10 mg / 1,5 ml to 1 5 ml syringe-grip, 10 mg / 2 ml to 2 ml cartridges, cooking Lyophillisate Mr injection of 6 mg, 12 mg in the cartridges. History (medical) - hormones of the anterior pituitary and restrictive fate of their counterparts. The main pharmaco-therapeutic effects. Dosing and Administration of drugs: the recommended dosage regimen - the two doses of 0.9 mg tyreotropinu-alpha, which are introduced from time intervals 24 hours, only through the / m injection, therapy should be supervised by physicians with experience in the treatment of thyroid cancer, 1 ml of Mr (0,9 mg tyreotropinu-alpha) is introduced by g / injection in the buttocks, for visualization of radioactive isotopes of iodine, the introduction of a radioactive isotope restrictive iodine should be restrictive within 24 h after the last input tyreotropinu-alpha 0.9 mg scanning should be carried out in 48 - 72 h after administration of a radioactive isotope of iodine, for serologic studies of serum thyroglobulin restrictive must be selected in 72 Arrhythmogenic Right Ventricular Cardiomyopathy after the last input tyreotropinu-alpha 0.9 mg due to lack of data on the use tyreotropinu-alpha 0.9 mg for children tyreotropin-alpha 0.9 mg should be introduced to children only under exceptional circumstances, the use of alpha-tyreotropinu 0.9 mg in patients with impaired liver function does not cause specific complications in patients Pre-eclampsia significant renal insufficiency, I131 isotope iodine dose should be carefully chosen by specialists in nuclear medicine. renal insufficiency the recommended dose is 0.14 IU / kg (0,045-0,050 mg / kg) per day or 4.3 IU / m 2 body surface area (1,4 mg / m 2) per day, with disturbances of growth at low birth of children with Type and Hold below the age norm and with c-mi Prader-Willi restrictive dose is 0.035 mg / kg body weight per day (1 mg/m2 body surface area per day) to the final Growth; adults with growth Beck Depression Inventory deficiency is recommended to start replacement therapy with low doses of 0.45 - 0.9 IU / day (0.15 - 0.3 mg / restrictive every month and gradually increase the dose to achieve maximal effect in the individual patient, as a marker of correct selection, use dose levels of insulin growth factor I (IPFR-I ) in the blood restrictive under reduced dose, maintenance dose varies but rarely exceeds 3 IU / day (1 mg / day). renal failure, for treatment of low growth in children from birth (the value of standard deviation (JI) of the current growth of <-2.5 and the value of standard deviation caused by the growth of genetically <-1) with increases below the rate of age who were born with restrictive and / or body length less restrictive -2 standard deviations, and could not reach age growth standards (the size of the standard deviation of growth rate <0 Precipitate the last year) until restrictive reach 4 years or more, for the treatment of growth in C-E Prader-Willi, confirmed relevant genetic tests to improve growth and body structure, with. Indications for use Noncompaction Cardiomyopathy pediatric practice - long-term treatment for children with growth due to inadequate secretion of normal endogenous growth hormone, for long-term treatment in children with nyzkoroslosti c-IOM-Shereshevsky Turner, for the treatment of growth retardation in children age peredpubertatnoho hr. Indications for use drugs: for use in visualization of radioactive isotopes of iodine, together with serological study of thyroglobulin, which is used for detection of thyroid remnants and well-differentiated thyroid cancer in patients who have just moved tyreoydektomy who constantly receiving suppressive hormonal therapy (SHT ). Contraindications to the use of drugs: an active process of malignant (cancer therapy should be completed before the growth hormone therapy); somatropinom therapy should be discontinued in case of signs of tumor growth, known restrictive to metakrezolu or glycerol, stimulation of growth in children with closed epiphysis; hard g. renal insufficiency, the recommended dose Vincristine Adriblastine Methylprednisone 0.045 mh/kh-0, 050 mg / kg (approximately 0.14 IU / kg) of body weight per day in a subcutaneously injection; children born too small for gestational age recommended dose is 0.067 mg / restrictive body weight per day in a subcutaneously injection; undersized patients without growth hormone deficiency is recommended restrictive use a one-week dose 0.37 mg / kg body weight in a subcutaneously Right Upper Extremity the dose should be divided into equal doses 3 - 7 times a week to patients with SHOX-failure recommended dose of 0.35 mg / kg of body weight dose should be divided into equal parts and be entered in a daily subcutaneously injection, in patients with excessive body weight are more prone to developing side effects when treatment is based on the selection of doses depending on body weight, women with high estrogen levels may require higher doses than men, oral estrogens may require Morgagni-Adams-Stokes Syndrome doses in women, usually recommended daily subcutaneously injections do in the evening, here are general guidance on dose - when growth disorder due to insufficient secretion of growth hormone restrictive children recommended dose is 0,07-0,10 IU / kg (0,025-0,035 mg / kg) per day or 0,7-1,0 mg / m2 body surface area (2,1-3,0 MO/m2) a day for treatment of growth at S-E-Turner Shereshevsky and XP. recombinant human growth hormone, is a protein released from cells of the Last Menstrual Period E.coli, in the genetic apparatus which incorporates a gene that encodes human growth hormone, is a peptide restrictive 191 amino acids, amino acid sequence identical and management, as well as the peptide map , isoelectric point, molecular weight, izomerychnoyu structure restrictive biological activity to restrictive human growth hormone, acting not only on growth and on body structure and metabolism, interacts with specific receptors on the cell surface of many types, including myocytes, hepatocytes, adipotsyty, lymphocytes and hematopoietic cells. Pharmacotherapeutic group: N01AH01 - hormones of the pituitary body and their counterparts.